Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 4/20 | 0.48 |
| ▸ | CTSS | P25774 | 4/20 | 0.48 |
| ▸ | CTSB | P07858 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.45 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2701065 | 1.00 | KYNU (0.52) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL19694732 | 1.00 | KYNU (0.52) | KYNUALDH1A1ALOX15SIRT2SIRT1 | |
| SCHEMBL7055671 | 0.92 | ITGB3 (0.53) | SIRT2SIRT1CTSLCTSSCTSB | |
| SCHEMBL20556338 | 0.92 | ITGB3 (0.53) | SIRT2SIRT1CTSLCTSSCTSB | |
| SCHEMBL7285522 | 0.92 | ITGB3 (0.53) | SIRT2SIRT1CTSLCTSSCTSB | |
| SCHEMBL1199066 | 0.88 | KYNU (0.54) | KYNUALDH1A1ALOX15CTSLCTSS | |
| SCHEMBL15936883 | 0.88 | KYNU (0.54) | KYNUALDH1A1ALOX15CTSLCTSS | |
| SCHEMBL1199068 | 0.88 | KYNU (0.54) | KYNUALDH1A1ALOX15CTSLCTSS | |
| SCHEMBL1261829 | 0.87 | PPARA (0.50) | CTSLCTSSCTSBCTSK | |
| SCHEMBL15354595 | 0.86 | ATM (0.53) | CTSLCTSSCTSBATMITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118176198-A | Nitrogen-containing tetracyclic compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-2274297-B1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-7741327-B2 | Pyrrolidinone glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | BERTHEL STEVEN JOSEPH | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | KYNU 1424/4885ALDH1A1 2381/4885ALOX15 1633/4885 |
| US-20090264445-A1 | PYRROLIDINONE GLUCOKINASE ACTIVATORS | GCKR, GCK, PDK2 | KYNU 939/4885ALDH1A1 1129/4885ALOX15 3068/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | KYNU 1087/4885ALDH1A1 1908/4885ALOX15 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.